/

ALPMY

Astellas Pharma, Inc.After hours

14.35−0.03 −0.21%USD

OTC Markets OTCPK · as of Oct 14, 15:59 ET · 15m delay

Open

14.32

Prev close

14.38

Day range

14.2514.37

52-week range

10.0517.35

Volume

17.70K0.14×

Mkt cap

25.73B

P/E ttm

10.87

Fwd P/E

31.89

EPS ttm

1.32

Div yield

3.44%

Earnings

Nov 4, 2026

From 52w high

−17.29%

Price Chart

Yahoo Finance · delayed

ALPMYOct 14, 2026O 14.32H 14.37L 14.25C 14.35−0.04 (−0.28%)Vol 17.70K

SMA 5014.74
SMA 20014.60

1Y change +36.67% since Oct 13, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ALPMY Astellas Pharma, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +0.77%
1 month: −3.37%
3 months: +9.21%
6 months: −12.82%
Year to date: +7.98%
1 year: +37.45%

Valuation & ownership

Market cap: 25.73B
Enterprise value: 372.74B
P/E (ttm): 10.87
Forward P/E: 31.89
PEG ratio: —
Price / book: 2.10
Price / sales (ttm): 0.01
EV / EBITDA: 0.56
EPS (ttm): 1.32
EPS (forward): 0.4500
Beta (5y monthly): 0.09
Dividend yield: 3.44%
Payout ratio: 37.07%
Shares outstanding: 1.79B
Float: 1.79B
Short % of float: —
Short ratio (days): —
Held by insiders: 0.00%
Held by institutions: 0.02%
Avg volume (3m): 125.01K
50-day average: 14.73
200-day average: 14.59
52-week change: +37.45%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): 44.2
vs 50-day SMA: −2.62%
vs 200-day SMA: −1.69%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 2.96%
Realised vol (20d, ann.): 20.3%
From 52-week high: −17.29%
From 52-week low: +42.79%

ANR

Analyst Consensus

1 analysts

Consensus

—

Mean target

17.40

+21.25% implied

Low 17.40Median 17.40High 17.40

Recommendation trend

Now1 / 0 / 0
1m ago1 / 0 / 0

Buy / hold / sell counts

DES

About Astellas Pharma, Inc.

Yahoo Finance profile

Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.

Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 14,099
Headquarters: Chuo, Japan
Website: astellas.com
Officers: Mr. Naoki Okamura BSc President, CEO & Representative Director
Mr. Katsuyoshi Sugita Executive VP, Chief People Officer & Representative Director
Mr. Atsushi Kitamura Chief Financial Officer

SEAS

Seasonality · ALPMY

2009–2026 · monthly returns

Strongest month Jan +2.90%Weakest month Mar −2.23%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	4.3	19.1	-1.8	-11.8	-0.8	-5.7	2.7	7.6	-2.1	-0.8			+8.0%
2025	0.2	0.3	-0.5	2.6	-0.8	-0.8	6.1	5.9	-0.6	-4.0	20.2	5.9	+37.6%
2024	-2.5	-5.8	-1.6	-11.2	2.7	0.5	17.7	6.9	-7.7	2.0	-11.1	-6.9	−18.8%
2023	-3.2	-4.6	1.4	5.8	5.0	-5.7	-1.6	3.5	-8.5	-8.4	-4.2	-2.1	−21.5%
2022	-0.7	3.3	-6.6	-2.6	4.9	-2.2	0.1	-9.4	-5.5	4.0	11.5	-1.9	−6.8%
2021	5.5	-2.6	-2.7	-2.8	8.1	7.2	-8.4	5.4	-1.5	2.2	-7.8	4.6	+5.4%
2020	3.5	-12.3	-1.4	7.3	9.1	-6.6	-5.8	-0.2	-4.9	-7.9	4.2	8.0	−9.3%
2019	17.9	6.0	-4.4	-11.4	0.8	6.4	-0.6	-2.5	3.4	21.1	-1.4	0.1	+35.8%
2018	4.0	11.0	4.4	-4.4	9.0	-4.8	7.3	4.0	3.0	-11.5	-0.6	-18.1	−1.1%
2017	-3.8	0.7	-1.9	-0.1	-4.7	-2.5	3.7	-0.8	0.8	4.8	-4.6	0.0	−8.5%
2016	-3.4	4.3	-7.8	1.8	-0.1	15.2	7.0	-8.4	2.3	-4.9	-6.4	-0.4	−3.1%
2015	10.1	2.8	3.7	-5.1	-6.6	-1.8	5.2	-1.3	-13.0	14.0	-4.1	1.6	+2.5%
2014	3.8	5.5	-8.4	-7.4	16.7	2.1	4.0	5.5	3.1	5.3	-8.2	-2.7	+17.6%
2013	12.9	6.7	-0.8	8.1	-11.2	5.2	-0.7	-5.2	0.2	9.2	6.5	0.0	+32.4%
2012	1.3	0.0	0.5	-1.4	-3.4	11.4	8.6	4.6	2.0	-2.1	2.5	-11.5	+11.1%
2011	2.2	1.6	-5.7	3.7	-1.0	2.5	-0.2	-3.0	0.2	-3.2	4.6	6.1	+7.4%
2010	-1.3	3.0	-3.9	-5.3	-7.1	4.8	0.9	1.2	5.4	2.8	-4.0	5.5	+1.0%
2009													—

CONG

Congress Trades · ALPMY

House and Senate reports since 2025

Members

1 last bought

Buys

~$8.0K

Sells

~$0

Net

+$8.0K

est. bought − sold

Latest

Mar 30, 26

Alan Armstrong

Members who traded it

Member	Buys	Sells	Est. net	Last move
Alan Armstrong Sen. OK	1		+$8.0K	Bought Mar 30, 26

Bought and sold by quarter (est.)

Members of Congress's ALPMY trades, newest first
Traded	Member	Owner	Type	Amount	Filed	Report
Mar 30, 26	Alan Armstrong Sen. OK	Self	Buy	$1,001 - $15,000	Jul 21, 26 (113d)	Report

From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades

ALPMY

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ALPMY

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Astellas Pharma, Inc.

Seasonality · ALPMY

Insider Activity · ALPMY

Congress Trades · ALPMY

Members who traded it

Bought and sold by quarter (est.)

Investors Holding ALPMY

Investors Holding ALPMY

Congress Trades · ALPMY

Members who traded it

Bought and sold by quarter (est.)

Insider Activity · ALPMY

Seasonality · ALPMY

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Astellas Pharma, Inc.

Financial Snapshot

Earnings & Dividends

News